AI orchestration platform reduces prior authorization times tenfold, freeing up clinical resources and improving patient access

Delays in prior authorization continue to hinder timely access to cancer treatment in the US. To tackle this bottleneck, RISA Labs has raised $3.5 million in seed funding to support wider deployment of its AI-based platform, which aims to reduce administrative burden in oncology and streamline access to care.

The round was led by Flipkart co-founder Binny Bansal, with additional participation from Oncology Ventures, General Catalyst, z21 Ventures, ODD BIRD VC, and Ashish Gupta. The company plans to scale its system to 100 additional cancer centers in the next two years.

According to Oncology Ventures, nearly 70% of cancer patients in the US face care delays due to prior authorization requirements. In a third of those cases, the delay can last a month—potentially increasing mortality risk by 13% for some cancer types.

RISA Labs’ platform—called the Business Operating System as a Service (BOSS)—is described by the company as a full-stack orchestration layer that integrates across institutional systems. Rather than relying on manual processes or traditional automation tools, the system breaks workflows into micro-tasks and delegates them to a network of AI agents, including large language models and digital twins.

Early deployment at a major US cancer center reportedly reduced prior authorization processing time from 30 minutes to under five, while freeing up 80% of associated staff time and lowering administrative costs by two-thirds. The system also handled over $1 million worth of oncology medications in a matter of months.

The founders, Kshitij Jaggi (CEO) and Kumar Shivang (CTO), are IIT Kanpur alumni and previous co-founders of Urban Health. Their experience with fragmented workflows in earlier ventures led to the development of RISA’s orchestration-first approach to health systems.

“Our goal is to simplify how institutions interact with complex software systems,” said Jaggi. “Rather than training more people to manage more tools, we’re using AI agents to interpret intent and take action.”

The company’s early research—published as Digital Twin Ecosystem in Oncology Clinical Operations—formed the basis of its AI approach, which it continues to refine. The system integrates with established healthcare records platforms such as Flatiron Health’s EMR.

Looking ahead, RISA Labs intends to expand its platform across other operational and clinical workflows in oncology. The company says it aims to support coordination between providers, life sciences organizations, and stakeholders involved in the drug delivery and care continuum.